Brenus Pharma raised $25M in a Series A funding round led by Angelor to accelerate clinical trials for its precision cancer vaccines.

Sep 18, 2024•over 1 year ago

Amount Raised

$25 Million

Round Type

series a

LyonTherapeuticsBiotechnologyHealth Care

Investors

Stéphane LegasteloisJacques GardetteInvestsudNoshaqCrédit Agricole Centre EstCrédit Agricole Centre FranceUi InvestissementAngelor

Description

Brenus Pharma, a biotech company developing cancer vaccines, has completed a $25 million Series A financing round. This funding will fully support the first-in-human proof-of-concept for its STC-1010 cancer vaccine.

Company Information

Company

Brenus Pharma

Location

Lyon, Auvergne Rhône Alpes, France

About

Brenus Pharma is a biotech company that specializes in the development of precision cancer vaccines. Their innovative technology platform, STC, utilizes an in-depth understanding of cancer complexity to create new treatment solutions. With a focus on transforming patient care, they aim to enhance immunotherapy outcomes for cancer patients. The company is dedicated to advancing its pipeline, featuring multiple candidates aimed at various solid tumor types.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends